NeuroPace CEO has 5,023 shares withheld for taxes
NeuroPace Inc’s CEO Joel Becker reported a tax-related share withholding.
Rhea-AI Filing Summary
NeuroPace Inc’s CEO Joel Becker reported a tax-related share withholding. On March 3, 2026, 5,023 shares of common stock were disposed of at $13.83 per share to satisfy tax withholding obligations tied to a restricted stock unit vesting. After this withholding, Becker directly owns 96,937 shares of NeuroPace common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise Price or Tax Liability: 5,023 shares
Exercise Price or Tax Liability
1 txn
Insider
Becker Joel
Role
CHIEF EXECUTIVE OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 5,023 | $13.83 | $69K |
Holdings After Transaction:
Common Stock — 96,937 shares (Direct)
Footnotes (1)
- F1. Represents the number of shares withheld by the Issuer on March 3, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award.
FAQ
What insider transaction did NeuroPace (NPCE) report for CEO Joel Becker?
NeuroPace reported that CEO Joel Becker had 5,023 shares withheld on March 3, 2026 to cover tax obligations from a restricted stock unit vesting. This is a tax-withholding disposition, not an open-market purchase or sale of shares.
Was Joel Becker’s NeuroPace (NPCE) Form 4 transaction an open-market sale?
No. The Form 4 describes a tax-withholding disposition coded “F,” where 5,023 shares were withheld by NeuroPace to meet tax obligations from an RSU vesting. It does not represent a voluntary open-market sale by CEO Joel Becker.
What does transaction code F mean in NeuroPace (NPCE) CEO’s Form 4?
Transaction code F indicates payment of exercise price or tax liability using shares. For Joel Becker, 5,023 shares were withheld by NeuroPace on March 3, 2026 to satisfy tax withholding obligations from a restricted stock unit vesting event.
AI-generated analysis. How Rhea-AI works. Not financial advice.